Zdrowie i gospodarka · 17/07/2024

FDA Extends Comment Period for Platform Technology Designation Program Draft Guidance

The US Food and Drug Administration (FDA) has extended the comment period for its draft guidance on the Platform Technology Designation Program for Drug Development, following requests from industry stakeholders for more time to submit comments.